Angelman syndrome

Last updated: February 23, 2023

Angelman syndrome

B1M2

B1M2

Fragile X syndrome
Turner syndrome
Turner syndrome: Year of the Zebra
Angelman syndrome
Prader-Willi syndrome
Miscellaneous genetic disorders: Pathology review
Gel electrophoresis and genetic testing
DNA mutations
Gene regulation
Oncogenes and tumor suppressor genes
Independent assortment of genes and linkage
Autosomal trisomies: Pathology review
Cellular structure and function
Nuclear structure
DNA structure
Cell cycle
DNA damage and repair
Mitosis and meiosis
Microtubule inhibitors
Karyotyping
DNA alkylating medications
Fluorescence in situ hybridization
Topoisomerase inhibitors
Anti-tumor antibiotics
Cytoskeleton and intracellular motility
Edwards syndrome (Trisomy 18)
Down syndrome (Trisomy 21)
Patau syndrome (Trisomy 13)
Klinefelter syndrome
Huntington disease
DNA synthesis inhibitors: Fluoroquinolones
DNA replication
Translation of mRNA
Transcription of DNA
Nucleotide metabolism
DNA synthesis inhibitors: Metronidazole
Gout
Lesch-Nyhan syndrome
Myotonic dystrophy
Ribonucleotide reductase inhibitors
Miscellaneous protein synthesis inhibitors
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Disorders of sex chromosomes: Pathology review
Williams syndrome
DiGeorge syndrome
Inheritance patterns
Human development week 3
Endoderm
Hedgehog signaling pathway
Development of the fetal membranes
Human development week 2
Miscarriage
Mesoderm
Ectoderm
Human development days 4-7
Human development days 1-4
Development of the placenta
Menstrual cycle
Pregnancy
Marfan syndrome
Hypertriglyceridemia
Hemophilia
Hemophilia: Year of the Zebra
Gaucher disease (NORD)
Phenylketonuria (NORD)
Ehlers-Danlos syndrome
Mendelian genetics and punnett squares
Hardy-Weinberg equilibrium
Approach to knee pain: Clinical sciences
Metaplasia and dysplasia
Breast cancer: Clinical
Colorectal polyps
Familial adenomatous polyposis
Colorectal cancer
Breast cancer
Chronic leukemia
Acute leukemia
Colorectal cancer: Clinical
Cushing syndrome
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Hypercalcemia
Respiratory distress syndrome: Pathology review
Sudden infant death syndrome
Environmental and chemical toxicities: Pathology review
Incidence and prevalence
Odds ratio
Relative and absolute risk
Positive and negative predictive value
Sensitivity and specificity
Test precision and accuracy
Case-control study
Cohort study
Cross sectional study

Transcript

Watch video only

Content Reviewers

Angelman syndrome is a genetic disorder that causes intellectual and developmental delay, seizures, frequent laughter, and ataxia, or poor control of voluntary movements.

Now, it happens when a gene on chromosome 15 called UBE3A is not expressed, or transcribed into messenger RNA.

UBE3A stands for ubiquitin-protein ligase E3A, and the protein it codes for is called E6AP or E6-associated protein.

The job of E6AP is to go around tagging, or attaching, a tiny protein called ubiquitin to other proteins, a process called ubiquitination.

Once that happens, the ubiquitinated protein is degraded by the proteasome, a part of the cell’s recycling machinery.

It’s kind of painting an orange U on a tree so that a lumberjack knows to chop it down.

So E6 associated protein has an important job, and it turns out that the region of chromosome 15 around UBE3A is imprinted, imprinting refers to gene expression that’s dependent on the parent of origin of a gene.

This means that either the maternally derived or paternally derived copy of the gene is silenced.

This differs from most genes in the genome, where both the maternal and paternal copies are expressed.

Normally, in the brain, only the maternally derived copy of UBE3A is expressed, while the paternal copy is silenced, unfortunately this process of imprinting leaves the maternal copy of UBE3A vulnerable.

So with the paternal copy of the gene imprinted, and epigenetically silenced, you’ve only got the maternal copy left.

So this means that if anything happens to the maternal copy, the result is Angelman syndrome.

There are a few different types of mutations that can cause Angelman syndrome.

The most common one is a deletion of a couple million base pairs of DNA on the maternal copy of chromosome 15 which includes UBE3A.

Sometimes the deletion overlaps a nearby gene called OCA2, which codes for a pigment that gives color to eye, hair, and skin.

As a result of this, these Angelman syndrome patients can have a light complexion.

A second way is a mutation within the maternal copy of UBE3A, making the protein ineffective.

A third way to get Angelman syndrome is when the entire maternal chromosome 15 is absent and instead there’s an extra copy of the paternal chromosome 15.

This scenario is called paternal uniparental disomy, which means that one parent – the father – contributed two of the same chromosome while the mother contributed none.

Key Takeaways

Angelman syndrome (AS) is a genetic neurodevelopmental disorder characterized by problems with motor skills, speech, developmental delay, and learning disabilities. People with AS typically have happy dispositions and frequently laugh or smile, even when they are not engaged in activities that would typically elicit such reactions.

Most individuals with AS do not develop fluent speech, have sleep disturbance, and usually have seizures. People with AS typically have a normal life expectancy and have the potential to improve on some self-help skills with proper supportive care.